06 Sep MBT-001 enhances natural killer (NK) cell function through thrombospondin-1 (TSP-1) signaling.
Our lead drug, MBT-001 was recently featured in Frontiers in Immunology for enhancing NK cells through the CD47-TSP-1 pathway. MBT-001 is the only CD47 treatment modality that inhibits both SIRPa “Don’t eat me” and TSP-1, thereby eliciting the full cancer-killing potential of CD47.
https://www.frontiersin.org/articles/10.3389/fimmu.2018.02985/full